Nanoform Finland Oyj Corporate Call Transcript
Good afternoon, all, and a warm welcome to Nanoform's webcast presentation and Q&A session. Today is January 26, and we have today press release promising clinical results, and we will present the conclusions on this call. My name is Henri von Haartman, and I'm your Director of Investor Relations. Today, our CEO, Edward Hæggström; CFO, Albert Hæggström; General Counsel, Peter Hänninen; and Chief Commercial Officer, Christian Jones, will present to you.
This presentation is webcasted through financial hearings. And after the presentation, we will hold a Q&A session, and it's possible to ask questions by calling in. Today, our CEO will start with controlled crystallization by CESS, the clinical trial conclusions, and the strategy going forward for this drug candidate. Our CFO will present the business opportunity within amorphous solid dispersions. Our General Counsel, Peter Hänninen, will present the IP position. Our Chief Commercial Officer will conclude with his views on the overall commercial impact from today's announced
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |